2,371 results on '"Jarnagin, William R"'
Search Results
202. Salvage hepatic artery infusion chemotherapy after first-line systemic failure in patients with unresectable cholangiocarcinoma.
203. Has management of locally advanced intrahepatic cholangiocarcinoma evolved with the evidence? Trends and practice patterns from the National Cancer Database.
204. Tumour extracellular vesicles and particles induce liver metabolic dysfunction
205. Risk Factors for Progression in Patients Undergoing Surveillance for Pancreatic Cysts
206. Hepatic disease control in patients with intrahepatic cholangiocarcinoma correlates with overall survival
207. Data from Tumor MHC Class I Expression Improves the Prognostic Value of T-cell Density in Resected Colorectal Liver Metastases
208. Supplementary Figures 1 - 2, Tables 1 - 2 from Tumor MHC Class I Expression Improves the Prognostic Value of T-cell Density in Resected Colorectal Liver Metastases
209. Figure S2 from Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection
210. Supplementary Tables from A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases
211. Supplementary Data from Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer
212. Supp FIgure 2 from Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care
213. Supplementary Figure 1 from Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
214. Supplementary Data from Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection
215. Supp FIgure 4 from Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care
216. Supplementary Table 1 from Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
217. Supplementary Data from Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care
218. Supplementary Table S1 from Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer
219. Multivariable prediction model for both 90-day mortality and long-term survival for individual patients with perihilar cholangiocarcinoma: does the predicted survival justify the surgical risk?
220. Sodium–glucose cotransporter 2 inhibitor-induced postoperative euglycaemic diabetic ketoacidosis after pancreatectomy
221. Early trends in serum phosphate and creatinine levels are associated with mortality following major hepatectomy
222. Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection
223. Central hepatectomy versus extended hepatectomy for liver malignancy: a matched cohort comparison
224. Intraductal Papillary Mucinous Neoplasms and the Risk of Diabetes Mellitus in Patients Undergoing Resection Versus Observation
225. The accuracy of pre-operative imaging in the management of hepatic cysts
226. Gallbladder Cancer: expert consensus statement
227. Outcomes after Resection of Intrahepatic Cholangiocarcinoma: External Validation and Comparison of Prognostic Models
228. Goal-Directed Fluid Therapy Using Stroke Volume Variation for Resuscitation after Low Central Venous Pressure-Assisted Liver Resection: A Randomized Clinical Trial
229. Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread
230. Prospective evaluation of 18F‐fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases
231. Simultaneous resection for rectal cancer with synchronous liver metastasis is a safe procedure
232. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma
233. Hepatic Parenchymal Preservation Surgery: Decreasing Morbidity and Mortality Rates in 4,152 Resections for Malignancy
234. Renal function after low central venous pressure‐assisted liver resection: assessment of 2116 cases
235. Chemotherapy-Induced Splenic Volume Increase Is Independently Associated with Major Complications after Hepatic Resection for Metastatic Colorectal Cancer
236. Texture Analysis of Preoperative CT Images for Prediction of Postoperative Hepatic Insufficiency: A Preliminary Study
237. The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer
238. Computed Tomography Image Texture: A Noninvasive Prognostic Marker of Hepatic Recurrence After Hepatectomy for Metastatic Colorectal Cancer
239. Utility of Serum Inflammatory Markers for Predicting Microvascular Invasion and Survival for Patients with Hepatocellular Carcinoma
240. Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014
241. Tumor-Associated Macrophage Infiltration in Colorectal Cancer Liver Metastases is Associated With Better Outcome
242. Percutaneous Peritoneal Lavage for the Rapid Staging of Gastric and Pancreatic Cancer
243. Actual 10-Year Survivors After Resection of Hepatocellular Carcinoma
244. Hospital readmissions after liver surgery for metastatic colorectal cancer
245. Distal Pancreatectomy: A Single Institution's Experience in Open, Laparoscopic, and Robotic Approaches
246. Model-Assisted Image-Guided Liver Surgery Using Sparse Intraoperative Data
247. Liver Anatomy: Variant Venous Anatomy and Implications for Resection
248. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma
249. Genetic heterogeneity of intrahepatic cholangiocarcinoma: Implications for outcome.
250. Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.